Eisai, Biogen
· 2d
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
New Maintenance Dosing Option for Alzheimer's Drug Leqembi Offers Flexibility
· 2d
Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing
Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA approved the maintenance dosing of once every four weeks after 18 months of the initiation phase of once every two weeks.
Ozempic, Novo Nordisk and type 2 diabetes
· 20h · on MSN
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
· 19h
F.D.A. Approves Ozempic to Treat Kidney Disease
· 16h
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Some results have been hidden because they may be inaccessible to you
Show inaccessible results